Chemodex

Aloe-Emodine

CHF 95.00
In stock
CDX-A0658-M05050 mgCHF 95.00
More Information
Product Details
Synonyms 1,8-Dihydroxy-3-(hydroxymethyl)anthraquinone; 3-Hydroxymethylchrysazine; Rhabarberone; Diacerein Impurity B; NSC 38628
Product Type Chemical
Properties
Formula

C15H10O5

MW 270.24
CAS 481-72-1
RTECS CB6712200
Source/Host Chemicals Plant
Purity Chemicals ≥98% (HPLC)
Appearance Yellow to orange powder.
Solubility Soluble in DMSO (2mg/ml) or DMF (5mg/ml). Insoluble in water.
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key YDQWDHRMZQUTBA-UHFFFAOYSA-N
Smiles OC1=C2C(C(C(C=C(CO)C=C3O)=C3C2=O)=O)=CC=C1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +4°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Aloe-emodin is a naturally anthraquinone derivative and an active ingredient of Aloe vera leaves and other plants. Aloe-emodin has been shown to exhibit many pharmacological effects, including anticancer, antivirus, anti-inflammatory, antibacterial, antiparasitic, neuroprotective, and hepatoprotective activities. It has potent laxative action by activating CFTR Cl- channels and inducing chloride secretion in colonic mucosa and releasing acetylcholine, which stimulates contraction of intestinal smooth muscle. It also demonstrates anti-tumor activity, inducing apoptosis in various cancer cells by increasing the production of reactive oxygen species (ROS) and induces apoptosis in glioma models through disruption of the mitochondria membrane potential. Aloe-emodin is reported to have estrogenic activity as a phytoestrogen, has been shown to inhibit breast cancer cell proliferation by downregulating ERα protein levels, and neuroprotective effects in vivo.

Product References

(1) T. Pecere, et al.; Cancer Res. 60, 2800 (2000) | (2) H. Matsuda, et al.; Bioorg. Med. Chem. Lett. 11, 1839 (2001) | (3) G. Srinivas, et al.; Med. Res. Rev. 27, 591 (2007) (Review) | (4) H. Yang, et al.; Acta Pharmacol. Sin. 32, 834 (2011) | (5) K. Liu, et al.; Carcinogenesis 33, 1406 (2012) | (6) J. Xu, et al.; Br. J. Pharmacol. 165, 197 (2012) | (7) P.H. Huang, et al.; Evid. Based Compl. Alternat. Med. 2013, 1 (2013) | (8) S. Ismail, et al.; J. Asian Nat. Prod. Res. 15, 1003 (2013) | (9) M.J. Xie, et al.; Asian Pac. J. Cancer Prev. 15, 5201 (2014) | (10) L. Tao, et al.; Bioorg. Med. Chem. Lett. 24, 5385 (2014) | (11) R. Chen, et al.; Am. J. Chin. Med. 42, 275 (2014) (Review) | (12) X. Dong, et al.; Phytother. Res. [Epub ahead of print] (2019) (Review)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.